Novoprotein Scientific Inc. (SHA:688137)
China · Delayed Price · Currency is CNY 132.20
-7.21 (-5.17%)
At close: Oct 19, 2026
Novoprotein Scientific Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 16, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 9,190 | 2,794 | 2,318 | 3,893 | 5,333 | - | |
Market Cap Growth | 217.15% | 20.54% | -40.46% | -27.00% | - | - |
Enterprise Value | 7,586 | 2,044 | 1,723 | 2,059 | 3,483 | - |
Last Close Price | 139.41 | 40.05 | 33.20 | 54.59 | 74.04 | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 16, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | 303.14 | 58.79 | - |
PS Ratio | 63.40 | 19.08 | 18.17 | 25.42 | 20.16 | - |
PB Ratio | 4.85 | 1.37 | 1.10 | 1.78 | 2.42 | - |
P/TBV Ratio | 4.89 | 1.39 | 1.11 | 1.79 | 2.44 | - |
P/FCF Ratio | - | - | - | 160.75 | - | - |
P/OCF Ratio | - | - | 174.09 | 56.30 | 1579.48 | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 16, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 52.91 | 13.96 | 13.51 | 13.44 | 13.17 | - |
EV/EBITDA Ratio | - | - | - | - | 38.49 | - |
EV/EBIT Ratio | - | - | - | - | 42.49 | - |
EV/FCF Ratio | - | - | - | 84.99 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 16, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.03 | 0.03 | 0.03 | 0.03 | 0.04 | 0.24 |
Debt / EBITDA Ratio | - | - | - | - | 0.81 | 0.47 |
Debt / FCF Ratio | - | - | - | 3.03 | - | 85.69 |
Net Debt / Equity Ratio | -0.80 | -0.81 | -0.82 | -0.83 | -0.82 | -0.28 |
Net Debt / EBITDA Ratio | 22.07 | 20.88 | 19.62 | 46.45 | -20.04 | -0.57 |
Net Debt / FCF Ratio | 16.19 | 17.93 | 54.96 | -75.00 | 54.32 | -100.78 |
Asset Turnover | 0.07 | 0.07 | 0.06 | 0.07 | 0.19 | 1.00 |
Inventory Turnover | 0.95 | 1.08 | 0.91 | 0.87 | 0.95 | 1.95 |
Quick Ratio | 17.78 | 25.76 | 27.90 | 39.37 | 31.89 | 4.03 |
Current Ratio | 18.76 | 26.84 | 29.13 | 41.30 | 33.35 | 4.63 |
Return on Equity (ROE) | -4.06% | -3.76% | -2.54% | 0.58% | 7.09% | 64.38% |
Return on Assets (ROA) | -2.51% | -2.64% | -2.78% | -1.33% | 3.60% | 32.15% |
Return on Invested Capital (ROIC) | -10.27% | -24.70% | -27.16% | -12.98% | 21.75% | 111.71% |
Return on Capital Employed (ROCE) | -4.30% | -4.40% | -4.70% | -2.20% | 3.60% | 39.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 16, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -0.85% | -2.78% | -2.35% | 0.33% | 1.70% | - |
FCF Yield | -1.02% | -3.30% | -1.36% | 0.62% | -0.63% | - |
Dividend Yield | - | - | - | 0.90% | 0.66% | - |
Payout Ratio | - | - | - | 273.19% | - | 10.93% |
Buyback Yield / Dilution | -0.17% | -0.45% | 2.23% | -25.05% | -42.83% | -151.52% |
Total Shareholder Return | -0.17% | -0.45% | 2.23% | -24.15% | -42.17% | -151.52% |